{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-JGYZSFXD/5eba76f8-0af6-4f21-8985-6ab57c4a5dd9/HTML","dcterms:extent":"33 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-JGYZSFXD/c6ec69b1-9aa2-4eab-9133-826e5817ecd1/PDF","dcterms:extent":"167 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-JGYZSFXD/70287c97-400e-4351-bbd0-8649f86ec9fe/TEXT","dcterms:extent":"28 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:DOC-JGYZSFXD","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2005","dc:creator":["Dermota, Urška","Grmek-Košnik, Irena","Juteršek, Borut"],"dc:format":[{"@xml:lang":"sl","#text":"številka:3"},{"@xml:lang":"sl","#text":"letnik:74"},{"@xml:lang":"sl","#text":"str. 159-163"}],"dc:identifier":["ISSN:1318-0347","COBISSID:19256025","URN:URN:NBN:SI:doc-JGYZSFXD"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"en","#text":"antibiotic"},{"@xml:lang":"en","#text":"Antibiotics"},{"@xml:lang":"sl","#text":"Antibiotiki"},{"@xml:lang":"en","#text":"bacteria"},{"@xml:lang":"sl","#text":"bakterije"},{"@xml:lang":"en","#text":"Community-Acquired Infections"},{"@xml:lang":"en","#text":"Electrophoresis, Gel, Pulsed-Field"},{"@xml:lang":"sl","#text":"Elektroforeza gelska, pulzirajoče-polje"},{"@xml:lang":"sl","#text":"Infekcije, domačega okolja"},{"@xml:lang":"en","#text":"Methicillin Resistance"},{"@xml:lang":"sl","#text":"Meticilinska rezistenca"},{"@xml:lang":"en","#text":"Microbial Sensitivity Tests"},{"@xml:lang":"sl","#text":"Mikrobni, občutljivostni testi"},{"@xml:lang":"sl","#text":"odpornost"},{"@xml:lang":"sl","#text":"stafilokoki"},{"@xml:lang":"sl","#text":"Stafilokokne infekcije"},{"@xml:lang":"en","#text":"Staphylococcal Infections"},{"@xml:lang":"en","#text":"Staphylococcus Aureus"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Proti meticilinu odporna bakterija Staphylococcus aureus domačega okolja (CA-MRSA)| Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA)|"},"dc:description":[{"@xml:lang":"sl","#text":"Background. Community acquired MRSA (CA-MRSA) infections affect patients without risk factors. CA-MRSA infections can be serious and also fatal even inpreviously healthy subjects. CA-MRSA differs from hospital acquired MRSA (HA-MRSA). CA-MRSA is more susceptible for non-beta-lactam antibiotics than HA-MRSA, has different PFGE subtypes, and can produce Panton-Valentine leukocidine. Methods. In Institute of Public Health Kranj we routinely performepidemiologic survey of MRSA positive patients. We compared MRSA isolates from patients with and without risk factors for acquisition of MRSA. We tested all S. aureus for their susceptibility to antibiotics (penicillin, oxacillin, vancomycin, gentamicin, erythromycin, clindamycin, tetracycline, cipro floxacine, chloramphenicol, trimethoprim sulfamethoxazole and rifampin).All CA-MRSA isolates were tested for susceptibility to fusidic acid staphylococcal enterotoxin (SE) production. We performed macrorestriction chromosome analysis with pulse field gel electrophoresis (PFGE). We compared CA-MRSA characteristics with epidemic MRSA strains. Results. In the period from 1999 to 2004 we isolated 1439 MRSA including 10 isolates suspicious for CA-MRSA. This isolates were susceptible for more than 5 antibiotics in contrast to epidemic MRSA which were susceptible for 3 or S antibiotics. Eightof 10 CA IVIRSA produced SE C or D or no SE, in contrast to epidemic MRSA, which produced exclusively SE A. In PFGE CA-MRSA showed different patterns compared to epidemic HA-MRSA. Conclusions. With exclusion of risk factors for MRSA acquisition in patient's history testing for antibiotic susceptibility, SE production and PFGE we proved that our MRSA isolates differed from ordinary epidemic strains. We identified CA-MRSA also in Slovenia"},{"@xml:lang":"sl","#text":"Izhodišča. Okužbe z MRSA se pojavljajo tudi zunaj bolnišnic. Izvirajo iz domačega okolja in prizadenejo ljudi brez dejavnikov tveganja. Okužbe z MRSA, pridobljene v domačem okolju (CA MRSA), so pri sicer zdravih ljudeh lahko resne ali celo smrtne. CA-MRSA se razlikuje od bolnišničnih sevov MRSA. CA-MRSA je bolj občutljiva za antibiotike, ki niso betalaktamski. Ima drugačnepodtipe PFGE (angl. pulsed field gel electrophoresis) in vsebuje lahkoPanton-Valentin levkocidin (PVL), ki ga bolnišnični sevi MRSA ne vsebujejo. Metode. V Laboratoriju za medicinsko mikrobiologijo Zavoda za zdravstveno varstvo Kranj delamo rutinsko epidemiološko analizo vseh bolnikov,pri katerih smo osamili povzročite ja MRSA. Primerjali smo značilnosti sevov MRSA, ki smo jih osamili pri bolnikih, ki so imeli dejavniketveganja za okužbo z MRSA, in seve iz kužnin bolnikov, ki niso imeli dejavnikov tveganja za okužbo z MRSA. Vsem sevom bakterije S. aureus smo določili občut jivost za antibiotike (penicilin, oksacilin, vankomicin, gentamicin, eritromicin, klindamicin, tetraciklin, ciprofloksacin, kloramfenikol, trimetoprim s sulfametoksazolom, rifampin). Vse seve bakterije CA-MRSA smo testirali na fusidinsko kislino in preiskali, ali proizvajajo stafilokokni enterotoksin (SE). Naredili smo makrorestrikcijsko analizo kromosomov z metodo gelske elektroforeze v utripajočem polju (PFGE). Značilnosti CA-MRSA smo primerjali z bolnišničnimi sevi MRSA. (Izvleček skrajšan pri 2000 znakih)"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:DOC-JGYZSFXD","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:DOC-JGYZSFXD"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:DOC-JGYZSFXD/c6ec69b1-9aa2-4eab-9133-826e5817ecd1/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:DOC-JGYZSFXD/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:DOC-JGYZSFXD"}}}}